SPONSOR
Shenzhen Geno-Immune Medical Institute
Total Trials
12
Recruiting
12
Phases
Phase 1, Phase 2, Phase 1
Conditions studied: T-cell Acute Lymphoblastic LeukemiaT-cell Acute Lymphoblastic LymphomaAcute Myeloid LeukemiaNK Cell LymphomaB Cell MalignanciesNeuroblastomaSolid TumorAdenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)Cancer DiseaseTreat and Prevent Covid-19 Infection
Shenzhen Geno-Immune Medical Institute is a clinical research sponsor with 12 registered studies on ClinicalTrials.gov, of which 12 are actively recruiting participants. Research covers conditions including T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma.
The trial portfolio spans Phase 1, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shenzhen Geno-Immune Medical Institute
How many clinical trials has Shenzhen Geno-Immune Medical Institute sponsored?
ClinicalMetric currently tracks 12 clinical trials sponsored by Shenzhen Geno-Immune Medical Institute, of which 12 are actively recruiting participants. These trials cover conditions including T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shenzhen Geno-Immune Medical Institute research focus on?
Shenzhen Geno-Immune Medical Institute clinical trials span T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma, B Cell Malignancies, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shenzhen Geno-Immune Medical Institute clinical trial?
To participate in a Shenzhen Geno-Immune Medical Institute trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shenzhen Geno-Immune Medical Institute trials with current recruitment status updated daily.
Clinical Trials by Shenzhen Geno-Immune Medical Institute
NCT04033302 Phase 1, Phase 2
Recruiting
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
T-cell Acute Lymphoblastic Leukemia
NCT05436496 Phase 1, Phase 2
Recruiting
CD19/70 Bi-specific CAR-T Cell Therapy
B Cell Malignancies
NCT04637503 Phase 1, Phase 2
Recruiting
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma
Neuroblastoma
NCT05437315 Phase 1, Phase 2
Recruiting
GD2/PSMA Bi-specific CAR-T Cell Therapy
Solid Tumor
NCT03645460
Recruiting
Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)
Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)
NCT05438368 Phase 1, Phase 2
Recruiting
GD2/CD70 Bi-specific CAR-T Cell Therapy
Cancer Disease
NCT03222674 Phase 1, Phase 2
Recruiting
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Acute Myeloid Leukemia
NCT04299724 Phase 1
Recruiting
Safety and Immunity of Covid-19 aAPC Vaccine
Treat and Prevent Covid-19 Infection
NCT04085159 Phase 1, Phase 2
Recruiting
Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis
Cancer
NCT05277753 Phase 1
Recruiting
NGS-MRD Assessment of Combination Immunotherapies Targeting T-ALL
T-Cell Acute Lymphoblastic Leukemia
NCT03271632 Phase 1, Phase 2
Recruiting
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Multiple Myeloma
NCT03184753 Phase 1, Phase 2
Recruiting
Genetically Modified T Cells Against Ovarian Cancer
Ovarian Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology